A Lxbio foi dis­tin­gui­da com o Out­stand­ing Inno­va­tion Award na 9th World Con­fer­ence on Tar­get­ing Phage Ther­a­py, real­iza­da em Valên­cia, Espan­ha, pelo desen­volvi­men­to da sua

Com base em ciên­cia, visão e propósi­to, a Lxbio Phar­ma­ceu­ti­cals afir­­ma-se como uma jovem bio­far­ma­cêu­ti­ca por­tugue­sa com ambição glob­al. Sob a lid­er­ança do seu CEO,

We are very pleased to announce the entry of a new investor into Lxbio Phar­ma­ceu­ti­cals S.A., rein­forc­ing the company’s momen­tum as it moves into its

Lxbio has inau­gu­rat­ed the first lab­o­ra­to­ry in the Iber­ian Penin­su­la ded­i­cat­ed to the devel­op­ment of CAR‑T cells and mon­o­clon­al anti­bod­ies, mark­ing a major mile­stone for

Strength­en­ing our Com­mit­ment to Advanc­ing Bac­te­rio­phage Research and Inno­va­tion! LxBio is offi­cial­ly a mem­ber of PhageEU, a Brus­sels-based coali­tion that aims to raise the poten­tial

Lxbio Phar­ma­ceu­ti­cals is pleased to announce that an invest­ment agree­ment has been signed with Explor­er SCR, a lead­ing invest­ment Fund in Por­tu­gal, an invest­ment with a glob­al

  Technophage , found­ing part­ner of Lxbio Phar­ma­ceu­ti­cals,  has attend­ed to ECCMID 2023. Togeth­er with the clin­i­cal team from Israel, it was pre­sent­ed the results

Nation­al Plat­form for the devel­op­ment and pro­duc­tion of Inno­v­a­tive Bio­phar­ma­ceu­ti­cals   Lxbio announces a new phase of the Bio-Hub mobi­liz­ing agen­da through the launch of